
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549**

FORM 8-K

**CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of report: **May 25, 2017 (May 25, 2017)**

PLURISTEM THERAPEUTICS INC.

(Exact Name of Registrant as Specified in Its Charter)

Nevada

(State or Other Jurisdiction of Incorporation)

001-31392

(Commission File Number)

**MATAM Advanced Technology Park
Building No. 5
Haifa, Israel**
(Address of Principal Executive Offices)

98-0351734

(IRS Employer Identification No.)

31905

(Zip Code)

011 972 74 710 7171

(Registrant's Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07. Submission of Matters to a Vote of Security Holders.

On May 25, 2017, Pluristem Therapeutics Inc. (the “Company”) held its 2017 Annual Meeting of Stockholders (the “2017 Annual Meeting”). The results of the stockholder voting at the 2017 Annual Meeting are set forth below:

Proposal No. 1 — Election of Directors

The stockholders elected the following individuals as directors of the Company to hold office until the next annual meeting of shareholders and until their successors shall have been duly elected and qualified.

<u>Director Name</u>	<u>For</u>	<u>Against</u>	<u>Abstain</u>	<u>Broker Non-Votes</u>
Zami Aberman	22,799,652	1,987,332	188,268	19,435,840
Israel Ben-Yoram	23,607,522	575,814	791,916	19,435,840
Isaac Braun	23,615,503	571,645	788,104	19,435,840
Mark Germain	23,625,763	563,739	785,750	19,435,840
Moria Kwiatt	22,899,597	1,855,606	220,049	19,435,840
Hava Meretzki	22,681,130	2,059,153	234,969	19,435,840
Nachum Rosman	24,159,423	574,496	241,333	19,435,840
Doron Shorrer	22,702,336	2,033,407	239,509	19,435,840
Yaky Yanay	22,848,791	1,994,757	131,704	19,435,840

Proposal No. 2 — Advisory Vote on the Compensation of our Named Executive Officers

<u>For</u>	<u>Against</u>	<u>Abstain</u>	<u>Broker Non-Votes</u>
18,941,992	5,696,599	336,661	19,435,840

Proposal No. 3 — Ratification of the selection of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as independent registered public accounting firm of the Company for the fiscal year ending June 30, 2017.

<u>For</u>	<u>Against</u>	<u>Abstain</u>	<u>Broker Non-Votes</u>
41,664,170	1,106,491	1,640,431	-

The results reported above are final voting results.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PLURISTEM THERAPEUTICS INC.

Date: May 25, 2017

By: /s/ Erez Egozi

Name: Erez Egozi

Title: Chief Financial Officer
